Tranzyme, Inc. (TZYM)
-NasdaqGM 0.61 
0.02(3.79%) May 24, 3:59PM EDT
| Prev Close: | 0.59 |
|---|
| Open: | 0.60 |
|---|
| Bid: | 0.40 x 1000 |
|---|
| Ask: | 0.83 x 1500 |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | 1.65 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.59 - 0.63 |
|---|
| 52wk Range: | 0.40 - 5.16 |
|---|
| Volume: | 371,185 |
|---|
| Avg Vol (3m): | 474,372 |
|---|
| Market Cap: | 16.92M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.68 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- TRANZYME INC FinancialsEDGAR Online Financials(Tue May 21)
- TRANZYME INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue May 14)
- 3 Health Care Stocks Under $10 to Watchat TheStreet(Thu May 9)
- Tranzyme Pharma Announces First Quarter 2013 Financial ResultsGlobeNewswire(Thu May 9)
- TRANZYME INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements anEDGAR Online(Thu May 9)
- Q1 2013 Tranzyme Inc Earnings Release - After Market CloseCCBN(Thu May 9)
- TRANZYME INC Files SEC form 8-K/A, Change in Directors or Principal Officers, Other EventsEDGAR Online(Fri May 3)
- Tranzyme Pharma to Report First Quarter 2013 Financial ResultsGlobeNewswire(Thu May 2)
- TRANZYME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,EDGAR Online(Mon Apr 29)
- TRANZYME INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed Apr 24)
- Tranzyme Pharma and Ocera Therapeutics Announce Merger AgreementGlobeNewswire(Tue Apr 23)
- Tranzyme Pharma Announces Fourth Quarter and Full-Year 2012 Financial ResultsGlobeNewswire(Thu Mar 28)
- TRANZYME INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu Mar 28)
- Q1 2013 Tranzyme Inc Earnings Release - After Market CloseCCBN(Thu Mar 28)
- Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial ResultsGlobeNewswire(Wed Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.53 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.47 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Tranzyme, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-based therapeutics primarily in the United States.
View More